DS
AVEO

DRW Securities’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

DRW Securities’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-5,986
Closed -$110K – 260
2013
Q4 		$110K Buy
5,986
+4
+0.1% +$80 ﹤0.01% 206
2013
Q3 		$129K Buy
+5,982
New +$137K 0.01% 147

Other funds holding AVEO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DRW Securities's AVEO Position: Q1 2014 in Review

DRW Securities sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2014, closing a stake of 5,986 shares — an estimated $110K sold.

DRW Securities first reported a position in AVEO in Q3 2013 and held it in 2 quarters. The position peaked at $129K in Q3 2013. 68 funds tracked by Wall St. Rank hold AVEO as of Q1 2014.

  • DRW Securities reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • DRW Securities sold 5,986 AVEO Pharmaceuticals, Inc. shares in Q1 2014, an estimated $110K.
  • DRW Securities first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2013 and held it in 2 quarters.
  • DRW Securities's AVEO Pharmaceuticals, Inc. position peaked at $129K in Q3 2013.
  • 68 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2014.

Based on DRW Securities's 13F filing for Q1 2014, filed 16 May 2014.